BJU Int

1. MARTIN A, Mahmoud AM, Britton CJ, Fadel A, et al
   In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.
   BJU Int. 2024 Nov 30. doi: 10.1111/bju.16598.
   

   >> Share

   
   
2. SII S, Papa N, Yiu TW, Tempo J, et al
   Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.
   BJU Int. 2024 Nov 28. doi: 10.1111/bju.16597.
   

   >> Share

   
   
3. ROBERTS MJ, Papa N, Veerman H, de Bie K, et al
   Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
   BJU Int. 2024;134 Suppl 2.
   

   >> Share

   
   
4. CRISAFI D, Wong BNX, Bolton D, Ischia J, et al
   Urologist underutilisation of androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
   BJU Int. 2024;134 Suppl 2:12-13.
   

   >> Share

   
   

   
   BMC Cancer

5. SATO K, Sakamoto S, Saito S, Shibata H, et al
   Time-dependent personalized prognostic analysis by machine learning in biochemical recurrence after radical prostatectomy: a retrospective cohort study.
   BMC Cancer. 2024;24:1446.
   

   >> Share

   
   
6. WU XH, Ke ZB, Chen ZJ, Liu WQ, et al
   Periprostatic fat magnetic resonance imaging based radiomics nomogram for predicting biochemical recurrence-free survival in patients with non-metastatic prostate cancer after radical prostatectomy.
   BMC Cancer. 2024;24:1459.
   

   >> Share

   
   
7. LI C, Jing Z, Guo Q, Zheng Z, et al
   Causal roles of dietary structure and types on prostate cancer risk: A mendelian randomization study.
   BMC Cancer. 2024;24:1476.
   

   >> Share

   
   

   
   Cancer

8. MUKAND NH, Chirikova E, Lichtensztajn D, Negoita S, et al
   Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake.
   Cancer. 2024;130:4298-4305.
   

   >> Share

   
   

   
   Cancer Lett

9. MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al
   PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer.
   Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355.
   

   >> Share

   
   

   
   Clin Cancer Res

10. HAFFNER MC, Morris MJ, Ding CC, Sayar E, et al
    Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2061.
    

    >> Share

    
    

    
    Eur Urol

11. MADEC FX, Mesnard B, Dariane C
    Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender Women.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02704-0. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
12. COOPERBERG MR
    Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02700-3. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    J Magn Reson Imaging

13. PARHIALA L, Knaapila J, Jambor I, Verho J, et al
    Long-Term Risk of Clinically Significant Prostate Cancer in Biopsy-Negative Patients With Baseline Biparametric Prostate MRI.
    J Magn Reson Imaging. 2024 Nov 27. doi: 10.1002/jmri.29668.
    

    >> Share

    
    

    
    Magn Reson Med

14. RIEDERER SJ, Borisch EA, Du Q, Froemming AT, et al
    Application of high-density 2D receiver coil arrays for improved SNR in prostate MRI.
    Magn Reson Med. 2025;93:850-863.
    

    >> Share

    
    

    
    Mod Pathol

15. FARYNA K, Tessier L, Retamero J, Bonthu S, et al
    Evaluation of Artificial Intelligence-Based Gleason Grading Algorithms "in the Wild".
    Mod Pathol. 2024;37:100563.
    

    >> Share

    
    

    
    Nat Rev Urol

16. BITARAF M, Ramasamy R, Punnen S, Sharifi N, et al
    Elevated periprostatic androgens, sneaky testosterone and its implications.
    Nat Rev Urol. 2024 May 7. doi: 10.1038/s41585-024-00878.
    

    >> Share

    
    
17. PALMER NR, Carroll PR, Washington SL 3rd
    Time is on our side - rethinking the concept of time to treatment for prostate cancer.
    Nat Rev Urol. 2024 Nov 29. doi: 10.1038/s41585-024-00977.
    

    >> Share

    
    

    
    Oncogene

18. RODRIGUES SOUSA E, de Brot S, Zoni E, Zeinali S, et al
    CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.
    Oncogene. 2024 Nov 26. doi: 10.1038/s41388-024-03230.
    

    >> Share

    
    
19. HUANG F, Li K, Chen Z, Cui Z, et al
    Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer.
    Oncogene. 2024 Nov 29. doi: 10.1038/s41388-024-03239.
    

    >> Share

    
    

    
    PLoS One

20. ANTON A, Hutchinson R, Hovens CM, Christie M, et al
    An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape.
    PLoS One. 2024;19:e0301943.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

21. VARUZHANYAN G, Chen CC, Freeland J, He T, et al
    PGC-1alpha drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
    Proc Natl Acad Sci U S A. 2024;121:e2416882121.
    

    >> Share

    
    

    
    Prostate

22. GLADIS PUSHPARATHI VP, Justin Xavier D, Chitra P, Kannan G, et al
    Prostate Cancer Classification and Interpretation With Multiparametric Magnetic Resonance Imaging and Gleason Grade Score Using DarkNet53 Model.
    Prostate. 2024 Nov 25:e24827. doi: 10.1002/pros.24827.
    

    >> Share

    
    
23. HE E, Li Y, Zhao R, Kong Q, et al
    IL7 as a Risk Factor for Prostate Cancer: Implications for T Cell Apoptosis and Infiltration in the Tumor Microenvironment.
    Prostate. 2024 Nov 26. doi: 10.1002/pros.24830.
    

    >> Share

    
    
24. MIYAHIRA AK, Sharifi M, Chesner LN, El-Kenawi A, et al
    Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Nov 27. doi: 10.1002/pros.24826.
    

    >> Share

    
    

    
    Urology

25. STEPHENS A, Morrison C, Lutchka J, Richard C, et al
    Prostate Cancer Screening and Diagnoses in the Transfeminine Population.
    Urology. 2024 Nov 21:S0090-4295(24)01083-5. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
26. MAGANTY A, Kaufman SR, Oerline MK, Faraj K, et al
    Commercial prices and care for Medicare beneficiaries with prostate cancer.
    Urology. 2024 Nov 22:S0090-4295(24)01055-0. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
27. HAYWOOD SC
    Editorial Comment on "PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience from a Multicenter Cohort".
    Urology. 2024 Nov 23:S0090-4295(24)01090-2. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share